These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31030436)

  • 1. [Clinical and genetic analysis of a patient with tyrosinemia type I but without elevated succinylacetone].
    Guo L; Jiao B; Liu F
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 May; 36(5):472-476. PubMed ID: 31030436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mutation analysis of FAH gene in patients with tyrosinemia type 1].
    Dou LM; Fang LJ; Wang XH; Lu W; Chen R; Li LT; Zhao J; Wang JS
    Zhonghua Er Ke Za Zhi; 2013 Apr; 51(4):302-7. PubMed ID: 23927806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Application of succinylacetone levels measurement in the blood and urine in the diagnosis of tyrosinemia type 1].
    Han LS; Ye J; Qiu WJ; Zhang HW; Wang Y; Ji WJ; Gao XL; Li XY; Jin J; Gu XF
    Zhonghua Er Ke Za Zhi; 2012 Feb; 50(2):126-30. PubMed ID: 22455637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of clinical data and genetic mutations in three Chinese patients with tyrosinemia type I].
    Yang N; Han LS; Ye J; Qiu WJ; Zhang HW; Gong ZW; Zhang YF; Wang Y; Gu XF
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Dec; 29(6):648-52. PubMed ID: 23225041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical features and genetic analysis of a child with acute form of Tyrosinemia type I due to a novel variant of FAH gene].
    Zhang Q; Zhang C; Wang Y; Wang W; Xu R; Hui L; Feng X; Wang X; Zheng L; Zhou B; Jiang Y; Hao S
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2023 Feb; 40(2):171-176. PubMed ID: 36709935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Screening for hereditary tyrosinemia and genotype analysis in newborns].
    Tong F; Yang R; Liu C; Wu D; Zhang T; Huang X; Hong F; Qian G; Huang X; Zhou X; Shu Q; Zhao Z
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2019 Jun; 48(4):459-464. PubMed ID: 31901053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The inclusion of succinylacetone as marker for tyrosinemia type I in expanded newborn screening programs.
    la Marca G; Malvagia S; Pasquini E; Innocenti M; Fernandez MR; Donati MA; Zammarchi E
    Rapid Commun Mass Spectrom; 2008; 22(6):812-8. PubMed ID: 18278819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Newborn screening for hepatorenal tyrosinemia: Tandem mass spectrometric quantification of succinylacetone.
    Sander J; Janzen N; Peter M; Sander S; Steuerwald U; Holtkamp U; Schwahn B; Mayatepek E; Trefz FK; Das AM
    Clin Chem; 2006 Mar; 52(3):482-7. PubMed ID: 16439608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved method to determine succinylacetone in dried blood spots for diagnosis of tyrosinemia type 1 using UPLC-MS/MS.
    Al-Dirbashi OY; Rashed MS; Jacob M; Al-Ahaideb LY; Al-Amoudi M; Rahbeeni Z; Al-Sayed MM; Al-Hassnan Z; Al-Owain M; Al-Zeidan H
    Biomed Chromatogr; 2008 Nov; 22(11):1181-5. PubMed ID: 18651606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maternal and fetal tyrosinemia type I.
    Garcia Segarra N; Roche S; Imbard A; Benoist JF; Grenèche MO; Davit-Spraul A; Ogier de Baulny H
    J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S507-10. PubMed ID: 23250512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel mutation causing mild, atypical fumarylacetoacetase deficiency (Tyrosinemia type I): a case report.
    Cassiman D; Zeevaert R; Holme E; Kvittingen EA; Jaeken J
    Orphanet J Rare Dis; 2009 Dec; 4():28. PubMed ID: 20003495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The genetic tyrosinemias.
    Scott CR
    Am J Med Genet C Semin Med Genet; 2006 May; 142C(2):121-6. PubMed ID: 16602095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stable isotope dilution analysis of succinylacetone using electron capture negative ion mass fragmentography: an accurate approach to the pre- and neonatal diagnosis of hereditary tyrosinemia type I.
    Jakobs C; Dorland L; Wikkerink B; Kok RM; de Jong AP; Wadman SK
    Clin Chim Acta; 1988 Feb; 171(2-3):223-31. PubMed ID: 3286060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of urinary succinylacetone by capillary electrophoresis for the diagnosis of tyrosinemia type I.
    Cansever MS; Erim FB
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Apr; 818(2):309-11. PubMed ID: 15734174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary Succinylacetone Analysis by Gas Chromatography-Mass Spectrometry (GC-MS).
    Chen H; Yu C
    Methods Mol Biol; 2016; 1378():281-90. PubMed ID: 26602140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous quantification of succinylacetone and nitisinone for therapeutic drug monitoring in the treatment of Tyrosinemia type 1.
    Sundberg J; Wibrand F; Lund AM; Christensen M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1072():259-266. PubMed ID: 29195145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and the importance of early treatment of tyrosinemia type 1: A case report.
    Škaričić A; Zekušić M; Fumić K; Rogić D; Uroić V; Petković Ramadža D; Žigman T; Barić I
    Clin Mass Spectrom; 2019 Apr; 12():1-6. PubMed ID: 34841073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of succinylacetone and the use of its measurement in mass screening for hereditary tyrosinemia.
    Grenier A; Lescault A; Laberge C; Gagné R; Mamer O
    Clin Chim Acta; 1982 Aug; 123(1-2):93-9. PubMed ID: 7116642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a novel, commercially available mass spectrometry kit for newborn screening including succinylacetone without hydrazine.
    Metz TF; Mechtler TP; Merk M; Gottschalk A; Lukačin R; Herkner KR; Kasper DC
    Clin Chim Acta; 2012 Aug; 413(15-16):1259-64. PubMed ID: 22521492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silent Tyrosinemia Type I Without Elevated Tyrosine or Succinylacetone Associated with Liver Cirrhosis and Hepatocellular Carcinoma.
    Blackburn PR; Hickey RD; Nace RA; Giama NH; Kraft DL; Bordner AJ; Chaiteerakij R; McCormick JB; Radulovic M; Graham RP; Torbenson MS; Tortorelli S; Scott CR; Lindor NM; Milliner DS; Oglesbee D; Al-Qabandi W; Grompe M; Gavrilov DK; El-Youssef M; Clark KJ; Atwal PS; Roberts LR; Klee EW; Ekker SC
    Hum Mutat; 2016 Oct; 37(10):1097-105. PubMed ID: 27397503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.